S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
What’s At Stake In April is Shocking (Ad)pixel
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
What’s At Stake In April is Shocking (Ad)pixel
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
What’s At Stake In April is Shocking (Ad)pixel
'War of the states': EV, chip makers lavished with subsidies
Lanterns and crescents: more retailers court Ramadan buyers
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
What’s At Stake In April is Shocking (Ad)pixel
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
What’s At Stake In April is Shocking (Ad)pixel
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
What’s At Stake In April is Shocking (Ad)pixel
'War of the states': EV, chip makers lavished with subsidies
Lanterns and crescents: more retailers court Ramadan buyers
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
What’s At Stake In April is Shocking (Ad)pixel
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
What’s At Stake In April is Shocking (Ad)pixel
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
What’s At Stake In April is Shocking (Ad)pixel
'War of the states': EV, chip makers lavished with subsidies
Lanterns and crescents: more retailers court Ramadan buyers
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
What’s At Stake In April is Shocking (Ad)pixel
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
What’s At Stake In April is Shocking (Ad)pixel
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
What’s At Stake In April is Shocking (Ad)pixel
'War of the states': EV, chip makers lavished with subsidies
Lanterns and crescents: more retailers court Ramadan buyers
NASDAQ:EVLO

Evelo Biosciences - EVLO Stock Forecast, Price & News

$0.18
+0.01 (+5.86%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.17
▼
$0.20
50-Day Range
$0.17
▼
$1.10
52-Week Range
$0.17
▼
$3.83
Volume
1.10 million shs
Average Volume
187,428 shs
Market Capitalization
$20.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.17

Evelo Biosciences MarketRank™ Forecast

Analyst Rating
Hold
1.75 Rating Score
Upside/​Downside
1,652.4% Upside
$3.17 Price Target
Short Interest
Bearish
2.58% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$160 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.74) to ($0.82) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.35 out of 5 stars

Medical Sector

847th out of 1,004 stocks

Pharmaceutical Preparations Industry

415th out of 489 stocks

See Top Rated MarketRank™ Stocks Here

EVLO stock logo

About Evelo Biosciences (NASDAQ:EVLO) Stock

Evelo Biosciences, Inc. operates as a clinical stage biotechnology company, which engages in the development of orally delivered investigational medicines. Its portfolio includes EDP1066 and EDP1815 for the treatment of inflammatory diseases, EDP2939 for inflammation, and EDP1908 for oncology. The company was founded by Noubar B. Afeyan and David A. Berry in 2014 and is headquartered in Cambridge, MA.

Receive EVLO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evelo Biosciences and its competitors with MarketBeat's FREE daily newsletter.

EVLO Stock News Headlines

March 23, 2023 | americanbankingnews.com
Stock Traders Buy High Volume of Put Options on Evelo Biosciences (NASDAQ:EVLO)
March 18, 2023 | seekingalpha.com
Evelo Biosciences, Inc. (EVLO) Q4 2022 Earnings Call Transcript
April 1, 2023 | Vantage Point (Ad)
Did You See These Trend Reversals?
Get ready for a potentially shocking and unprecedented announcement from the Fed meeting on May 3rd. This could cause many retail and industry traders to resort to drastic measures. One swift stroke could make popular assets plummet, BUT… there’s a straightforward solution to act now to protect your family and wealth. pixel
March 16, 2023 | finance.yahoo.com
Evelo Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
March 15, 2023 | msn.com
Earnings Preview: Evelo Biosciences
March 9, 2023 | finance.yahoo.com
Evelo Biosciences to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 16, 2023
March 1, 2023 | finance.yahoo.com
After Plunging -40.39% in 4 Weeks, Here's Why the Trend Might Reverse for Evelo Biosciences, Inc. (EVLO)
March 1, 2023 | finance.yahoo.com
Evelo Biosciences to Participate in the Cowen 43rd Annual Health Care Conference
April 1, 2023 | Legacy Research (Affiliate) (Ad)
"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast.
February 27, 2023 | finance.yahoo.com
Evelo Biosciences Reports that EDP2939, its First Oral Extracellular Vesicle Product Candidate, Commenced Dosing in a Phase 2 Psoriasis Trial
February 13, 2023 | finance.yahoo.com
Down -39.46% in 4 Weeks, Here's Why Evelo Biosciences, Inc. (EVLO) Looks Ripe for a Turnaround
February 1, 2023 | msn.com
Why WestRock Company Are Trading Lower By 13%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
February 1, 2023 | msn.com
Evelo Biosciences sheds 48 employees after skin disease treatment fails
February 1, 2023 | finance.yahoo.com
Evelo Biosciences' Atopic Dermatitis Study Fails, Observes Unusually High Placebo Response Rates
February 1, 2023 | finance.yahoo.com
Flagship-backed biotech cuts nearly half its staff
February 1, 2023 | msn.com
Evelo drops 23% as atopic dermatitis trial fails; announces layoffs
February 1, 2023 | reuters.com
Evelo Biosciences to cut jobs, skin disease drug trial disappoints
February 1, 2023 | finance.yahoo.com
Evelo Biosciences Provides Clinical and Business Updates
February 1, 2023 | finance.yahoo.com
UPDATE 1-Evelo Biosciences to cut jobs, skin disease drug trial disappoints
January 11, 2023 | finance.yahoo.com
Horizon Technology Finance Provides Fourth Quarter 2022 Portfolio Update
December 14, 2022 | finance.yahoo.com
Senda Biosciences Appoints MIT Institute Professor Paula Hammond, Ph.D., to Its Board of Directors
December 1, 2022 | finance.yahoo.com
Evelo Biosciences, Inc. (NASDAQ:EVLO) insiders placed bullish bets worth US$575k in the last 12 months
November 15, 2022 | finanznachrichten.de
Evelo Biosciences, Inc.: Evelo Biosciences Reports Third Quarter 2022 Financial Results and Business Highlights
November 15, 2022 | finance.yahoo.com
Evelo Biosciences Announces Publication of Scientific Basis for SINTAX Medicines in Frontiers in Immunology
November 15, 2022 | finance.yahoo.com
Evelo Biosciences Reports Third Quarter 2022 Financial Results and Business Highlights
November 8, 2022 | finance.yahoo.com
Evelo Biosciences to Present at the 2022 Jefferies London Healthcare Conference
September 7, 2022 | finance.yahoo.com
Evelo Biosciences Presents Biomarker Data Demonstrating Anti-inflammatory Effects of EDP1815 in Psoriasis at the 2022 European Academy of Dermatology and Venereology (EADV) Congress
See More Headlines
Receive EVLO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evelo Biosciences and its competitors with MarketBeat's FREE daily newsletter.

EVLO Company Calendar

Last Earnings
10/27/2021
Today
4/01/2023
Next Earnings (Estimated)
5/11/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EVLO
CUSIP
N/A
CIK
1694665
Web
www.evelobio.com
Phone
(617) 577-0300
Fax
N/A
Employees
122
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.17
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+1,652.4%
Consensus Rating
Hold
Rating Score (0-4)
1.75
Research Coverage
4 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.45)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-114,530,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-1,975.63%
Return on Assets
-142.49%

Debt

Debt-to-Equity Ratio
3.93
Current Ratio
4.16
Quick Ratio
4.16

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.05) per share
Price / Book
-3.61

Miscellaneous

Outstanding Shares
110,930,000
Free Float
101,834,000
Market Cap
$20.05 million
Optionable
Not Optionable
Beta
1.37

Key Executives

  • Simba Gill
    President, Chief Executive Officer & Director
  • Ann Marella Thorell
    Chief Financial Officer, Treasurer & Senior VP
  • Mark W. Bodmer
    Chief Scientific Officer, President-R&D
  • Chun Zhang
    Chief Technical Operations & Quality Officer
  • Andrea Itano
    Senior Vice President & Head-Research

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













EVLO Stock - Frequently Asked Questions

Should I buy or sell Evelo Biosciences stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evelo Biosciences in the last year. There are currently 1 sell rating and 3 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" EVLO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EVLO, but not buy additional shares or sell existing shares.
View EVLO analyst ratings or view top-rated stocks.

What is Evelo Biosciences' stock price forecast for 2023?

4 Wall Street research analysts have issued 1 year price objectives for Evelo Biosciences' shares. Their EVLO share price forecasts range from $2.00 to $5.00. On average, they predict the company's share price to reach $3.17 in the next year. This suggests a possible upside of 1,652.4% from the stock's current price.
View analysts price targets for EVLO or view top-rated stocks among Wall Street analysts.

How have EVLO shares performed in 2023?

Evelo Biosciences' stock was trading at $1.61 at the start of the year. Since then, EVLO stock has decreased by 88.8% and is now trading at $0.1807.
View the best growth stocks for 2023 here.

When is Evelo Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023.
View our EVLO earnings forecast.

How were Evelo Biosciences' earnings last quarter?

Evelo Biosciences, Inc. (NASDAQ:EVLO) announced its earnings results on Wednesday, October, 27th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.54) by $0.09. During the same period last year, the company posted ($0.45) earnings per share.

What other stocks do shareholders of Evelo Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Evelo Biosciences investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), Evofem Biosciences (EVFM), Sorrento Therapeutics (SRNE), Cerecor (CERC), Myovant Sciences (MYOV), Provention Bio (PRVB), VBI Vaccines (VBIV), VYNE Therapeutics (VYNE) and Aldeyra Therapeutics (ALDX).

When did Evelo Biosciences IPO?

(EVLO) raised $85 million in an initial public offering on Wednesday, May 9th 2018. The company issued 5,300,000 shares at a price of $15.00-$17.00 per share. Morgan Stanley, Cowen and BMO Capital Markets served as the underwriters for the IPO and JMP Securities was co-manager.

What is Evelo Biosciences' stock symbol?

Evelo Biosciences trades on the NASDAQ under the ticker symbol "EVLO."

How do I buy shares of Evelo Biosciences?

Shares of EVLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Evelo Biosciences' stock price today?

One share of EVLO stock can currently be purchased for approximately $0.18.

How much money does Evelo Biosciences make?

Evelo Biosciences (NASDAQ:EVLO) has a market capitalization of $20.05 million. The company earns $-114,530,000.00 in net income (profit) each year or ($1.45) on an earnings per share basis.

How many employees does Evelo Biosciences have?

The company employs 122 workers across the globe.

How can I contact Evelo Biosciences?

Evelo Biosciences' mailing address is 620 Memorial Drive Suite 500 West, Cambridge MA, 02139. The official website for the company is www.evelobio.com. The company can be reached via phone at (617) 577-0300 or via email at ir@evelobio.com.

This page (NASDAQ:EVLO) was last updated on 4/1/2023 by MarketBeat.com Staff